Smithfield Trust Co Acquires 1,490 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Smithfield Trust Co increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 76.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,428 shares of the company’s stock after buying an additional 1,490 shares during the period. Smithfield Trust Co’s holdings in Takeda Pharmaceutical were worth $49,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TAK. Millennium Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 87.1% in the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after acquiring an additional 2,023,707 shares during the period. Van ECK Associates Corp boosted its stake in Takeda Pharmaceutical by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares during the period. Cowen AND Company LLC bought a new position in Takeda Pharmaceutical in the 2nd quarter worth about $6,866,000. Pathstone Holdings LLC grew its holdings in Takeda Pharmaceutical by 1.0% during the 3rd quarter. Pathstone Holdings LLC now owns 430,676 shares of the company’s stock valued at $6,124,000 after buying an additional 4,280 shares in the last quarter. Finally, Summit Global Investments increased its position in shares of Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after buying an additional 192,143 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

TAK stock opened at $13.38 on Friday. The firm has a 50 day moving average of $14.10 and a 200-day moving average of $13.83. The firm has a market capitalization of $42.57 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 0.25 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.